ARVO was last week and there was a ton of research discussed. One thing presented at the conference that you may start hearing more about in 2019 is Brolucizumab, an anti-VEGF drug currently in Phase 3 trials for the treatment of wet AMD.

How is this anti-VEGF different than the others?
Three main differences.
1. The molecular size.
2. The drug concentration.
3. The time between injections.

Brolucizumab is the smallest anti-VEGF molecule tested in humans. The small size allows for better tissue penetration and the ability to give higher drug concentrations. These two things lengthen the treatment effect, increasing the time between injections.

Tell me about the study results.
Previous study results have shown that at a 12-week dosing interval, more patients were found to have less active wet AMD disease than Eylea patients. These new results show that when “12-week dosing with brolucizumab is initially successful, there is high probability that the patient will maintain this interval through the first year of treatment.” (via)